TGF-β in the pathogenesis and prevention of disease: A matter of aneurysmic proportions

Journal of Clinical Investigation

Volumn 120, Issue 2, 2010, Pages 403-407

  Dietz, Harry C ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II; CHEMOKINE RECEPTOR CCR2; FIBRILLIN 1; GAMMA SARCOGLYCAN; INITIATION FACTOR 4E BINDING PROTEIN; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; NEUTRALIZING ANTIBODY; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

ABDOMINAL AORTA ANEURYSM; ALLELE; ANEURYSM; APOPTOSIS; ASCENDING AORTA; BIOAVAILABILITY; CARCINOGENESIS; CELL CYCLE ARREST; CELL DIFFERENTIATION; DISEASE COURSE; DISSECTION; DUCHENNE MUSCULAR DYSTROPHY; GENETIC CODE; HEART ATRIUM MYXOMA; HUMAN; HYPOPLASIA; LENS LUXATION; LIMB GIRDLE MUSCULAR DYSTROPHY; MACROPHAGE; MARFAN SYNDROME; MOUSE; MUSCULAR DYSTROPHY; MYOPATHY; NONHUMAN; NOTE; PATHOGENESIS; PRIORITY JOURNAL; PROPHYLAXIS; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; UPREGULATION; VASCULITIS;

ANIMALS; AORTIC ANEURYSM; CHILD; DISEASE MODELS, ANIMAL; HUMANS; LATENT TGF-BETA BINDING PROTEINS; MALE; MARFAN SYNDROME; MICE; MUSCLE FIBERS, SKELETAL; MUSCLE, SKELETAL; MUSCULAR DISEASES; MUSCULAR DYSTROPHIES; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 76649100088     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI42014     Document Type: Note

References (41)

1. Markowitz S, et al. Inactivation of the type II TGFbeta receptor in colon cancer cells with microsatellite instability. Science. 1995;268(5215):1336-1338.
2. Tian M, Schiemann WP. The TGF-beta paradox in human cancer: an update. Future Oncol. 2009;5(2):259-271.
3. Potenta S, Zeisberg E, Kalluri R. The role of endothelial-to-mesenchymal transition in cancer progression. Br J Cancer. 2008;99(9):1375-1379.
4. Wipff PJ, Rifkin DB, Meister JJ, Hinz B. Myofibroblast contraction activates latent TGFbeta1 from the extracellular matrix. J Cell Biol. 2007;179(6):1311-1323.
5. Ramirez F, Dietz HC. Marfan syndrome: from molecular pathogenesis to clinical treatment. Curr Opin Genet Dev. 2007;17(3):252-258.
6. Neptune ER, et al. Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome. Nat Genet. 2003;33(3):407-411.
7. Ng CM, et al. TGF-beta-dependent pathogenesis of mitral valve prolapse in a mouse model of Marfan syndrome. J Clin Invest. 2004;114(11):1586-1592.
8. Habashi JP, et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science. 2006;312(5770):117-121.
9. Cohn RD, et al. Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states. Nat Med. 2007;13(2):204-210.
10. Brooke BS, Habashi JP, Judge DP, Patel N, Loeys B, Dietz HC 3rd. Angiotensin II blockade and aorticroot dilation in Marfan's syndrome. N Engl J Med. 2008;358(26):2787-2795.
11. Lacro RV, et al. Rationale and design of a randomized clinical trial of beta-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome. Am Heart J. 2007;154(4):624-631.
12. Hanada K, et al. Perturbations of vascular homeostasis and aortic valve abnormalities in fibulin-4 deficient mice. Circ Res. 2007;100(5):738-746.
13. Coucke PJ, et al. Mutations in the facilitative glucose transporter GLUT10 alter angiogenesis and cause arterial tortuosity syndrome. Nat Genet. 2006;38(4):452-457.
14. Gomez D, et al. Syndromic and non-syndromic aneurysms of the human ascending aorta share activation of the Smad2 pathway. J Pathol. 2009; 218(1):131-142.
15. Loeys BL, et al. Aneurysm syndromes caused by mutations in the TGF-beta receptor. N Engl J Med. 2006;355(8):788-798.
16. Loeys BL, et al. A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2. Nat Genet. 2005;37(3):275-281.
17. Mizuguchi T, et al. Heterozygous TGFBR2 mutations in Marfan syndrome. Nat Genet. 2004;36(8):855-860.
18. Maleszewski JJ, Miller DV, Lu J, Dietz HC, Halushka MK. Histopathologic findings in ascending aortas from individuals with Loeys-Dietz syndrome (LDS). Am J Surg Pathol. 2009;33(2):194-201.
19. Choudhary B, Zhou J, Li P, Thomas S, Kaartinen V, Sucov HM. Absence of TGFbeta signaling in embryonic vascular smooth muscle leads to reduced lysyl oxidase expression, impaired elastogenesis, and aneurysm. Genesis. 2009;47(2):115-121.
20. Heydemann A, et al. Latent TGF-β-binding protein 4 modifies muscular dystrophy in mice. J Clin Invest. 2009;119(12):3703-3712.
21. Cassis LA, et al. ANG II infusion promotes abdominal aortic aneurysms independent of increased blood pressure in hypercholesterolemic mice. Am J Physiol Heart Circ Physiol. 2009;296(5):H1660-H1665.
22. Wang Y, et al. TGF-β activity protects against inflammatory aortic aneurysm progression and complications in angiotensin II-infused mice. J Clin Invest. 2010;120(2):422-432.
23. King VL, et al. Interferon-gamma and the interferon-inducible chemokine CXCL10 protect against aneurysm formation and rupture. Circulation. 2009; 119(3):426-435.
24. Daugherty A, Manning MW, Cassis LA. Antagonism of AT2 receptors augments angiotensin IIinduced abdominal aortic aneurysms and atherosclerosis. Br J Pharmacol. 2001;134(4):865-870.
25. Cassis LA, Rateri DL, Lu H, Daugherty A. Bone marrow transplantation reveals that recipient AT1a receptors are required to initiate angiotensin II-induced atherosclerosis and aneurysms. Arterioscler Thromb Vasc Biol. 2007;27(2):380-386.
26. Henriques T, Zhang X, Yiannikouris FB, Daugherty A, Cassis LA. Androgen increases AT1a receptor expression in abdominal aortas to promote angiotensin II-induced AAAs in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2008; 28(7):1251-1256.
27. Fujiwara Y, et al. Inhibition of experimental abdominal aortic aneurysm in a rat model by the angiotensin receptor blocker valsartan. Int J Mol Med. 2008;22(6):703-708.
28. Inoue N, et al. Involvement of vascular angiotensin II-forming enzymes in the progression of aortic abdominal aneurysms in angiotensin II- infused ApoE-deficient mice. J Atheroscler Thromb. 2009; 16(3):164-171.
29. Tieu BC, et al. An adventitial IL-6/MCP1 amplification loop accelerates macrophage-mediated vascular inflammation leading to aortic dissection in mice. J Clin Invest. 2009;119(12):3637-3651.
30. Ishibashi M, et al. Bone marrow-derived monocyte chemoattractant protein-1 receptor CCR2 is critical in angiotensin II-induced acceleration of atherosclerosis and aneurysm formation in hypercholesterolemic mice. Arterioscler Thromb Vasc Biol. 2004;24(11):e174-178.
31. Lee EY, et al. The monocyte chemoattractant protein-1/CCR2 loop, inducible by TGF-beta, increases podocyte motility and albumin permeability. Am J Physiol Renal Physiol. 2009;297(1):F85-F94.
32. Park JI, et al. Transforming growth factor-beta1 activates interleukin-6 expression in prostate cancer cells through the synergistic collaboration of the Smad2, p38-NF-kappaB, JNK, and Ras signaling pathways. Oncogene. 2003;22(28):4314-4332.
33. Seong GJ, et al. TGF-beta-induced interleukin-6 participates in transdifferentiation of human Tenon's fibroblasts to myofibroblasts. Mol Vis. 2009; 15:2123-2128.
34. Zhang F, et al. Transforming growth factor-beta promotes recruitment of bone marrow cells and bone marrow-derived mesenchymal stem cells through stimulation of MCP-1 production in vascular smooth muscle cells. J Biol Chem. 2009;284(26):17564-17574.
35. Eickelberg O, et al. Transforming growth factorbeta1 induces interleukin-6 expression via activating protein-1 consisting of JunD homodimers in primary human lung fibroblasts. J Biol Chem. 1999; 274(18):12933-12938.
36. Dagouassat M, et al. Monocyte chemoattractant protein-1 (MCP-1)/CCL2 secreted by hepatic myofibroblasts promotes migration and invasion of human hepatoma cells. Int J Cancer. 2010;126(5):1095-1108.
37. Pinchuk IV, et al. Monocyte chemoattractant protein-1 production by intestinal myofibroblasts in response to staphylococcal enterotoxin a: relevance to staphylococcal enterotoxigenic disease. J Immunol. 2007;178(12):8097-8106.
38. Afzali B, Mitchell P, Lechler RI, John S, Lombardi G. 2009. Translational Mini-Review Series on Th17 Cells: induction of interleukin-17 production by regulatory T cells. Clin Exp Immunol. [published online ahead of print Nov 11 2009]. doi: 10.1111/ j.1365-2249.2009.04038.x.
39. Yanagisawa H, et al. Fibulin-5 is an elastin-binding protein essential for elastic fibre development in vivo. Nature. 2002;415(6868):168-171.
40. Nakamura T, et al. Fibulin-5/DANCE is essential for elastogenesis in vivo. Nature. 2002; 415(6868):171-175.
41. Loeys B, et al. Homozygosity for a missense mutation in fibulin-5 (FBLN5) results in a severe form of cutis laxa. Hum Mol Genet. 2002;11(18):2113-2118.